GW 117
Alternative Names: GW-117Latest Information Update: 18 Feb 2025
Price :
$50 *
At a glance
- Originator Beijing Greatway Pharmaceutical Technology
- Class Antidepressants; Small molecules
- Mechanism of Action 5-HT2C serotonin receptor antagonists; Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 24 Mar 2023 Beijing Greatway Pharmaceutical Technology completes a phase-I trials in Major depressive disorder (In volunteers) in China (Sublingual) (CTR20221750)
- 13 Jul 2021 Phase-I clinical trials in Major depressive disorder (In volunteers) in China (Sublingual) (CTR20221750)